- Home
- M vs MRUS Comparison
M vs MRUS Comparison
Compare M & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- M
- MRUS
- Stock Information
- Founded
- M 1830
- MRUS 2003
- Country
- M United States
- MRUS Netherlands
- Employees
- M N/A
- MRUS N/A
- Industry
- M Department/Specialty Retail Stores
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- M Consumer Discretionary
- MRUS Health Care
- Exchange
- M Nasdaq
- MRUS Nasdaq
- Market Cap
- M 4.1B
- MRUS 3.6B
- IPO Year
- M N/A
- MRUS 2016
- Fundamental
- Price
- M $14.78
- MRUS $43.64
- Analyst Decision
- M Buy
- MRUS Strong Buy
- Analyst Count
- M 7
- MRUS 10
- Target Price
- M $19.86
- MRUS $86.70
- AVG Volume (30 Days)
- M 4.9M
- MRUS 400.6K
- Earning Date
- M 11-26-2024
- MRUS 10-31-2024
- Dividend Yield
- M 4.78%
- MRUS N/A
- EPS Growth
- M N/A
- MRUS N/A
- EPS
- M 0.65
- MRUS N/A
- Revenue
- M $23,509,000,000.00
- MRUS $35,932,000.00
- Revenue This Year
- M N/A
- MRUS N/A
- Revenue Next Year
- M N/A
- MRUS $52.49
- P/E Ratio
- M $22.25
- MRUS N/A
- Revenue Growth
- M N/A
- MRUS N/A
- 52 Week Low
- M $14.06
- MRUS $22.26
- 52 Week High
- M $22.10
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- M 39.57
- MRUS 33.36
- Support Level
- M $14.95
- MRUS $42.30
- Resistance Level
- M $15.66
- MRUS $53.49
- Average True Range (ATR)
- M 0.46
- MRUS 2.29
- MACD
- M -0.10
- MRUS -1.02
- Stochastic Oscillator
- M 7.26
- MRUS 17.69
About M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 500 stores under the Macy's nameplate, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's nameplates, and 157 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances composed 62% of Macy's 2023 sales.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.